1. Home
  2. SAGE
  3. SAGE News

Latest Sage Therapeutics Inc. (SAGE) News on February 23, 2025

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
SAGE

TipRanks

10 days ago

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
SAGE

Zacks

10 days ago

Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y

SAGE

Thomson Reuters StreetEvents

11 days ago

Q4 2024 SAGE Therapeutics Inc Earnings Call

Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...
SAGE

GuruFocus.com

11 days ago

Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
SAGE

Zacks

11 days ago

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
SAGE

Business Wire

11 days ago

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
SAGE

Zacks

19 days ago

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
SAGE

Zacks

24 days ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
SAGE

Zacks

24 days ago

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
SAGE

Business Wire

25 days ago

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
SAGE

Zacks

25 days ago

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

Sage rejects Biogen’s $469m takeover bid
SAGE

Pharmaceutical Technology

a month ago

Sage rejects Biogen’s $469m takeover bid

SAGE

MT Newswires

a month ago

Sector Update: Health Care Stocks Gain Monday Afternoon

SAGE

MT Newswires

a month ago

Update: Sage Therapeutics Board Rejects Biogen's Unsolicited Acquisition Bid

SAGE

MT Newswires

a month ago

SAGE Therapeutics Board Rejects Biogen's Unsolicited Acquisition Bid

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
SAGE

Reuters

a month ago

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
SAGE

Business Wire

a month ago

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
SAGE

Zacks

a month ago

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
SAGE

TipRanks

a month ago

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist

Biogen bid for Sage does not change narrative, says BMO Capital
SAGE

TipRanks

a month ago

Biogen bid for Sage does not change narrative, says BMO Capital

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
SAGE

Zacks

a month ago

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?

Biogen proposes acquisition of partner Sage Therapeutics
SAGE

Pharmaceutical Technology

a month ago

Biogen proposes acquisition of partner Sage Therapeutics

Biogen Offers to Buy Remaining Stake in Sage Therapeutics
SAGE

Zacks

a month ago

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Biogen Wants to Buy Its Partner Sage for Almost No Premium
SAGE

Barrons.com

a month ago

Biogen Wants to Buy Its Partner Sage for Almost No Premium

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
SAGE

Investopedia

a month ago

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
SAGE

Benzinga

a month ago

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
SAGE

Barrons.com

a month ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
SAGE

BioPharma Dive

a month ago

Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street

SAGE

MT Newswires

a month ago

SAGE Therapeutics Receives Unsolicited $7.22 Per Share Acquisition Proposal From Biogen

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference
SAGE

Business Wire

a month ago

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
SAGE

Business Wire

a month ago

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

Biogen proposes to buy remaining stake in Sage in $442 million deal
SAGE

Reuters

a month ago

Biogen proposes to buy remaining stake in Sage in $442 million deal

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
SAGE

Business Wire

a month ago

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Wall Street Analysts Believe Sage Therapeutics (SAGE) Could Rally 42.02%: Here's is How to Trade
SAGE

Zacks

2 months ago

Wall Street Analysts Believe Sage Therapeutics (SAGE) Could Rally 42.02%: Here's is How to Trade

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
SAGE

Zacks

2 months ago

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

Sage Therapeutics price target lowered to $6 from $10 at Stifel
SAGE

TipRanks

2 months ago

Sage Therapeutics price target lowered to $6 from $10 at Stifel

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
SAGE

Business Wire

3 months ago

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Sage Therapeutics price target lowered to $4 from $7 at BofA
SAGE

TipRanks

3 months ago

Sage Therapeutics price target lowered to $4 from $7 at BofA

SAGE

MT Newswires

3 months ago

Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
SAGE

Zacks

3 months ago

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

Sage ends dalzanemdor development following Phase II trial failure
SAGE

Clinical Trials Arena

3 months ago

Sage ends dalzanemdor development following Phase II trial failure

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
SAGE

Zacks

3 months ago

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
SAGE

Benzinga

3 months ago

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

SAGE

MT Newswires

3 months ago

Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating

SAGE

MT Newswires

3 months ago

SAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints

Sage’s string of research failures continues
SAGE

BioPharma Dive

3 months ago

Sage’s string of research failures continues

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
SAGE

Business Wire

3 months ago

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
SAGE

TipRanks

4 months ago

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
SAGE

Zacks

4 months ago

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Biogen, Sage admit a defeat in major depression
SAGE

BioPharma Dive

4 months ago

Biogen, Sage admit a defeat in major depression

Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
SAGE

GuruFocus.com

4 months ago

Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
SAGE

Zacks

4 months ago

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
SAGE

Business Wire

4 months ago

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
SAGE

Zacks

4 months ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
SAGE

Zacks

4 months ago

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

State Street Corp's Strategic Acquisition of Sage Therapeutics Shares
SAGE

GuruFocus.com

4 months ago

State Street Corp's Strategic Acquisition of Sage Therapeutics Shares

Sage Therapeutics to Reduce Workforce by 33%, Stock Down
SAGE

Zacks

4 months ago

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

Sage lays off 55% of R&D workforce and refocuses pipeline
SAGE

Pharmaceutical Technology

4 months ago

Sage lays off 55% of R&D workforce and refocuses pipeline

Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
SAGE

GuruFocus.com

4 months ago

Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
SAGE

Benzinga

4 months ago

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce

Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
SAGE

Barrons.com

4 months ago

Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.

Sage to cut one-third of workforce, streamline drug pipeline
SAGE

BioPharma Dive

4 months ago

Sage to cut one-third of workforce, streamline drug pipeline

SAGE

MT Newswires

4 months ago

SAGE Therapeutics to Cut Workforce by 33%, or 165 Workers, in Reorganization

Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
SAGE

Business Wire

4 months ago

Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
SAGE

Business Wire

4 months ago

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Sage Therapeutics price target lowered to $8 from $9 at Wedbush
SAGE

TipRanks

4 months ago

Sage Therapeutics price target lowered to $8 from $9 at Wedbush

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
SAGE

Zacks

4 months ago

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study

Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment
SAGE

Barrons.com

4 months ago

Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
SAGE

Benzinga

4 months ago

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study

SAGE

MT Newswires

4 months ago

Sector Update: Health Care

Sage continues downslide as Alzheimer’s study fails
SAGE

BioPharma Dive

4 months ago

Sage continues downslide as Alzheimer’s study fails

Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
SAGE

Barrons.com

4 months ago

Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment

SAGE

Investing.com

4 months ago

Sage Therapeutics stock drops after disappointing Alzheimer's trial results

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
SAGE

Business Wire

4 months ago

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease

Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
SAGE

Zacks

5 months ago

Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why

SAGE

MT Newswires

5 months ago

Sector Update: Health Care Stocks Steady Late Afternoon

SAGE

MT Newswires

5 months ago

Sector Update: Health Care Stocks Softer Friday Afternoon

SAGE

Investing.com

5 months ago

Sage stock slides as RBC cuts rating to Sell on trial results concerns

SAGE

MT Newswires

5 months ago

Sage Therapeutics Faces High-Risk Outlook Amid Concerns Over Success in Phase 2 Huntington's Disease Trial, RBC Says

SAGE

MT Newswires

5 months ago

RBC Downgrades Sage Therapeutics to Sector Perform From Outperform, Adjusts Price Target to $4 From $10

Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now
SAGE

Insider Monkey

5 months ago

Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
SAGE

Zacks

5 months ago

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends
SAGE

TipRanks

5 months ago

SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
SAGE

Benzinga

5 months ago

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate

SAGE

MT Newswires

5 months ago

Sage Therapeutics Says Biogen Discontinues Collaboration on Sage-324 Program

Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
SAGE

Business Wire

5 months ago

Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program

Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers
SAGE

Insider Monkey

5 months ago

Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers

SAGE

MT Newswires

5 months ago

Sage Therapeutics Files Registration Statement for Planned Mixed-Shelf Offering

Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?
SAGE

Zacks

6 months ago

Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?

SAGE

MT Newswires

6 months ago

Truist Adjusts Price Target on Sage Therapeutics to $13 From $18, Maintains Hold Rating

Analysts Have Been Trimming Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target After Its Latest Report
SAGE

Simply Wall St.

7 months ago

Analysts Have Been Trimming Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target After Its Latest Report

Sage Therapeutics Second Quarter 2024 Earnings: Misses Expectations
SAGE

Simply Wall St.

7 months ago

Sage Therapeutics Second Quarter 2024 Earnings: Misses Expectations

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
SAGE

Zacks

7 months ago

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
SAGE

Zacks

7 months ago

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
SAGE

Business Wire

7 months ago

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
SAGE

Zacks

7 months ago

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

SAGE

MT Newswires

7 months ago

TD Cowen Downgrades Sage Therapeutics to Hold From Buy, Adjusts Price Target to $10 From $16

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
SAGE

Zacks

7 months ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical

SAGE

MT Newswires

7 months ago

Baird Adjusts Price Target on Sage Therapeutics to $13 From $15, Maintains Neutral Rating

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
SAGE

Zacks

7 months ago

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?

Share on Social Networks: